Extracellular matrix metalloproteinase inducer (EMMPRIN) remodels the extracellular matrix through enhancing matrix metalloproteinases (MMPs) and inhibiting tissue inhibitors of MMPs expression in HPV-positive cervical cancer cells

Purpose of investigation: To study the expression of extracellular matrix metalloproteinase inducer (EMMPRIN), matrix metalloproteinases (MMPs), and tissue inhibitors of MMP (TIMPs) in uterine cervical cancer cell lines in vitro. Materials and Methods: EMMPRIN, MMPs, and TIMPs expression were assessed by Western blot and real-time RT-PCR from cervical carcinoma SiHa, HeLa, and C33-A cells. Results: EMMPRIN recombinant significantly increased MMP-2, MMP-9 protein and mRNA expression in SiHa and Hela cells, but not in C33-A cells by Western blot analysis and real-time RT-PCR. EMMPRIN recombinant significantly inhibited TIMP-1 protein and mRNA levels in SiHa and Hela cells, but not in C33-A cells. There was no difference on the TIMP-2 expression in those cells with the treatment of EMMPRIN recombinant. EMMPRIN RNAi decreased MMP-2 and MMP-9 and increased TIMP-1 expression in SiHa and HeLa cells, but not in C33-A cells. There was no change on the expression of TIMP-2 mRNA levels in SiHa, HeLa and C33-A cells transfected with siEMMPRIN. Conclusions: EMMPRIN may induce MMP-2 and MMP-9, and downregulate TIMP-1 in HPV-positive cervical cancer cells in vitro.

Extracellular matrix metalloproteinase inducer (EMMPRIN); Matrix metalloproteinases (MMPs); Tissue inhibitors of MMP (TIMP); Cervical carcinoma.

[1] Parkin D.M., Bray F., Ferlay J., Pisani P.: “Global cancer statistics”. 2002. CA Cancer J. Clin., 2005, 55, 74.

[2] Beaudenon S., Huibregtse J.M..: “HPV E6, E6AP and cervical cancer”. BMC Biochem., 2008, 21, S4.

[3] Lizarraga F., Espinosa M., Maldonado V., Melendez-Zajgla J.: “Tis-sue inhibitor of metalloproteinases-4 is expressed in cervical cancer patients”. Anticancer Res., 2005, 25, 623.

[4] Liotta L.A., Rao C.N., Barsky S.H.: “Tumor invasion and the extra-cellular matrix”. Lab. Invest., 1983, 49, 636.

[5] Giannelli G., Falk-Marzillier J., Schiraldi O., Stetler-Stevenson W. G., Quaranta V.: “Induction of cell migration by matrix metallo-proteinase-2 cleavage of laminin-5”. Science, 1997, 277, 225.

[6] Sheu B.C., Lien H.C., Ho H.N., Lin H.H., Chow S.N., Huang S.C., Hsu S.M. et al.: “Increased expression and activation of gelatinolytic matrix metalloproteinases is associated with the progression and re-currence of human cervical cancer”. Cancer Res., 2003, 63, 6537.

[7] Iacono K.T., Brown A.L., Greene M.I., Saouaf S.J.: “CD147 im-munoglobulin superfamily receptor function and role in pathology”. Exp. Mol. Pathol., 2007, 83, 283.

[8] Muraoka K., Nabeshima K., Murayama T., Biswas C., Koono M.: “Enhanced expression of a tumor–cellderived collagenase-stimulatory factor in urothelial carcinoma: its usefulness as a tumor marker for bladder cancers”. Int. J. Cancer, 1993, 55, 19.

[9] Marieb E.A., Zoltan-Jones A., Li R.: “Emmprin promotes anchor-age-independent growth in human mammary carcinoma cells by stimulating hyaluronan production”. Cancer Res., 2004, 64, 1229.

[10] Kanekura T., Chen X., Kanzaki T.: “Basigin (CD147) is expressed on melanoma cells and induces tumor cell invasion by stimulating production of matrix metalloproteinases by fibroblast”. Int J Cancer, 2002, 99, 520.

[11] Schmidt R., Bültmann A., Ungerer M., Joghetaei N., Bülbül O., Thieme S., et al.: “Extracellular matrix metalloproteinase inducer regulates matrix metalloproteinase activity in cardiovascular cells: im-plications in acute myocardial infarction”. Circulation, 2006, 113, 834.

[12] Lambert E., Dassé E., Haye B., Petitfrère E.: “TIMPs as multifacial proteins”. Crit. Rev. Oncol. Hematol., 2004, 49, 187.

[13] Nuovo G.J., MacConnell P.B., Simsir A., Valea F., French D.L.: “Correlation of the in situ detection of polymerase chain reactionamplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma”. Cancer Res., 1995, 55, 267.

[14] Biswas C., Zhang Y., DeCastro R., Guo H., Nakamura T., Kataoka H., et al.: “The human tumor cell-derived collagenase stimulatory factor (renamed EMMPRIN) is a member of the immunoglobulin superfamily”. Cancer Res., 1995, 55, 434.

[15] Li Y, Xu J, Chen L, Zhong WD, Zhang Z, Mi L et al.: “HAb18G (CD147), a cancer-associated biomarker and its role in cancer detection”. Histopathology., 2009, 54, 677-687.

[16] Tsai W.C., Sheu L.F., Nieh S., Yu C.P., Sun G.H., Lin Y.F., et al.: “Association of EMMPRIN and fascin expression in renal cell carcinoma: correlation with clinicopathological parameters”. World J. Urol., 2007, 25, 73.

[17] Xu Q., Ohara N., Liu J., Amano M., Sitruk-Ware R., Yoshida S., et al.: “Progesterone receptor modulator CDB-2914 induces extracel-lular matrix metalloproteinase inducer in cultured human uterine leiomyoma cells”. Mol. Hum. Reprod., 2008, 14, 181.

[18] Yi-Jun Xue, Qiang Lu, Zhi-Xi Sun.: “CD147 overexpression is a prognostic factor and a potential therapeutic target in bladder can-cer”. Med Oncol., 2011, 28, 1363.

[19] Kapral M., Wawszczyk J., Jurzak M., Dymitruk D., Weglarz L.: “Evaluation of the expression of metalloproteinases 2 and 9 and their tissue inhibitors in colon cancer cells treated with phytic acid”. Acta Pol Pharm., 2010, 67, 625.

[20] Zou W., Yang H., Hou X., Zhang W., Chen B., Xin X.: “Inhibition of CD147 gene expression via RNA interference reduces tumor cell invasion, tumorigenicity and increase chemosensitivity to paclitaxel in HO-8910pm cells”. Cancer Lett., 2007, 248, 211.

[21] Li Y., Shang P., Qian A.R., Wang L., Yang Y., Chen Z.N.: “Inhibitory effects of antisense RNA of HAb18G/CD147 on invasion of hepato-cellular carcinoma cells in vitro”. World J. Gastroenterol., 2003, 9, 2174.

[22] Clark I.M., Rowan A.D., Edwards D.R., Bech-Hansen T., Mann D. A., Bahr M.J., Cawston T.E.: “Transcriptional activity of the human tissue inhibitor of metalloproteinases 1 (TIMP-1) gene in fibroblasts involves elements in the promoter, exon 1 and intron 1”. Biochem., 1997, 324, 611.

[23] Reddy V.S., Prabhu S.D., Mummidi S., Valente A.J., Venkatesan B., Shanmugam P., Delafontaine P., Chandrasekar B.: “Interleukin-18 induces EMMPRIN expression in primary cardiomyocytes via JNK/Sp1 signalingand MMP-9 in part va EMPRIN and through AP-1 and Nk-kappaB activation”. Am. J. Physiol. Heart Circ. Physiol., 2010, 299, 1242.

[24] Del Toro-Arreola S., Arreygue-Garcia N., Aguilar-Lemarroy A., Cid-Arregui A., Jimenez-Perez M., Haramati J., et al.: “MHC class I-re-lated chain A and B ligands are differentially expression in human cervical cancer cell lines”. Cancer Cell Int., 2011, 1,11.

[25] Sun D., Wang X., Zhang H., Deng L., Zhang Y.: “MMP-9 mediates MICA shedding in human osteosarcomas”. Cell Biol Int., 2011, 35, 569.